Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
March 20, 2024
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, everyone, and thank you for being with us on our earnings call and business update for the fourth quarter and year-end 2023. With me on this call today are two of my colleagues: Lisa Delfini, who serves as Trevi's Chief Financial Officer, and Dr. David Clark, Trevi's Chief Medical Officer. Lisa and I will share some prepared remarks, and after that, we'll open the line for questions. The fourth quarter of 2023 and the beginning of 2024 proved to be a productive period for Trevi, as we initiated 3 clinical studies. Let me give you a quick update on each of these trials. I'll start with our Phase IIa River trial in refractory chronic cough, which got underway in Q4 of 2023. Refractory chronic cough, or RCC, is a debilitating disease affecting up to 10% of adults, and it is defined as a persistent cough lasting greater than 8 weeks despite treatment for an underlying condition. RCC results from cough reflex hypersensitivity in the central and peripheral nerves, and it has a significant physical, psychological and social impact on patients. Given the multiple drug failures in this space and the absence of any approved therapies for RCC in the U.S., a significant unmet and urgent need persists for new potential treatments. The key differentiator for Haduvio in refractory chronic cough is its mechanism of action, which works synergistically both centrally in the brain and peripherally in the lungs. Our belief is that Haduvio's central and peripheral mechanism could potentially work in more patients and may deliver a stronger effect across a broader range of baseline cough counts compared with peripheral-only mechanisms such as the P2X3 inhibitors. For clinical trial purposes, RCC patients have been stratified into 3 categories of frequency: very high, meaning greater than 20 coughs per hour; high to moderate, meaning 10 to 19 coughs per hour; and low frequency coughers. According to the KOLs, both the very high and the high to moderate frequency coughers are considered to have severe cough. To date, the P2X3 have only demonstrated statistical significance in the very high cough counters and have not shown successful results at a cough frequency of 10 to 19 coughs per hour; we believe that based on the data from our IPF cough trial, which showed a strong drug effect across all baseline cough counts, and the drug's central and peripheral mechanism of action, Haduvio has the potential to work in patients broadly across varying cough frequencies. Looking at the RCC patient distribution, an estimated 44% of patients have moderate to high cough frequency, while only an estimated 29% have very high cough frequency. So Haduvio potentially may address close to 3/4 of the RCC market, whereas P2X3s may only be effective in less than 1/3 of the market. Now on to the details of our RCC trial, which follows the standard design used across several cough trials run to date. The RIVER trial is a Phase IIa study that's double-blind, randomized, placebo-controlled, with a 2-period crossover design, and it's assessing cough reduction in roughly 60 patients. Randomization for these patients will use one-to-one stratification, splitting between individuals coughing 10 to 19 times hourly and those coughing more than 20 times hourly. Every treatment period spans 3 weeks, with a 3-week washout separating them. For patients receiving Haduvio, the dose gets titrated each week, starting at 27 milligrams and going up to 108 milligrams taken twice daily throughout the dosing period. When it comes to the primary efficacy endpoint, it's the relative change in 24-hour cough frequency at day 21 from the treatment period baseline, comparing Haduvio against placebo, as measured through an objective cough monitor. Secondary endpoints will also be explored in this study, among them patient-reported outcome measures covering cough and quality of life. We're thrilled to have gotten this study underway and anticipate having substantially all sites activated before this month ends. Our expectation for top line data from this study remains the second half of this year. Now, moving to an update on our lead program in idiopathic pulmonary fibrosis, or IPF, chronic cough. IPF is a severe end-of-life disease. Roughly 85% of patients battling IPF report chronic cough, which carries physical, psychological, and social impacts as significant as those of RCC; it might additionally serve as a risk factor contributing to IPF progression. Persistent coughing can cause continual lung injury, micro tears, and possible inflammation, which may result in worse health outcomes for patients, like more respiratory hospitalizations, mortality, or the need for a transplant. Since no approved treatments currently exist for chronic cough in IPF, patients and providers face an urgent need for new therapies. Although numerous development programs for IPF are ongoing, therapies both current and in development haven't demonstrated an effect on chronic cough, which is one of these patients' primary complaints, heightening the unmet need. At the close of 2023, we launched a Phase IIb study for chronic cough in IPF, called the CORAL study. CORAL is a 4-arm Phase IIb dose-ranging trial set to examine 3 active doses of Haduvio alongside placebo. This 6-week trial involves approximately 160 patients; we intend to run it across multiple countries and sites so enrollment can be finished in a timely manner. Site activations are progressing in multiple countries, and enrollment is at early stages. We reconfirm our guidance for top line data from this study in the first half of 2025, assuming no changes arise from our sample size reestimation results, which we expect in the second half of this year. Finally, we began dosing in the last part of the human abuse potential, or HAP, study in January of this year. This final portion of the HAP study uses a randomized, double-blind, double-dummy 5-way crossover design to establish the abuse potential of 3 doses of oral nalbuphine compared with the selected dose of IV butorphanol and placebo. What we're mainly trying to do here is assess how much people like nalbuphine when it's set against placebo and butorphanol, and the main measure we're using is a VAS scale for drug liking. Keep in mind that when nalbuphine is given parenterally, the DEA does not schedule it. Things are progressing well with this trial, and enrollment has now gone beyond the 50% point. We still anticipate having top line data from this trial during the back half of this year too. So as you can tell, it's a clinically busy period for Trevi, and in our view the results from these studies will matter a great deal in shaping how we move forward with developing Haduvio and for chronic cough conditions. What drives us is the chance to bring patients suffering from these serious conditions and chronic cough an effective option. At this point I'll hand things to Lisa so she can go through our financial results, and after that we'll take whatever questions you might have.
Lisa Delfini
executiveThanks, Jennifer, and good afternoon, everyone. The full financial results for the 3 months ended December 31, 2023 are available in our press release issued prior to this call, as well as in our 10-K, which was filed with the SEC today after the market closed. During the fourth quarter of 2023, we posted a net loss of $7.8 million, compared with a net loss of $5.5 million in the same quarter of 2022. R&D expenses totaled $6.5 million in the fourth quarter of 2023, versus $4.3 million in the same quarter of 2022. That increase was primarily attributable to greater clinical trial costs for our Phase IIb CORAL trial and our Phase IIa RIVER trial, both of which commenced in the fourth quarter of 2023. G&A expenses remained essentially flat, at $2.4 million in the fourth quarter of 2023 compared with $2.3 million in the same period of 2022. We take a highly disciplined approach to managing cash, so even as R&D expenses rose with the launch of 4 clinical trials, G&A expenses have stayed level. Other income net was $1.1 million in both the fourth quarter of 2023 and 2022, primarily from interest income on our cash balances, offset by any interest expense. We repaid our term loan in May of 2023, so interest expense was de minimis in the fourth quarter of 2023. At December 31, 2023, our cash, cash equivalents and marketable securities stood at $83 million, compared with $120.5 million at December 31, 2022. Our cash runway guidance — that we will have cash, cash equivalents and marketable securities into 2026 — remains unchanged, and we believe it is sufficient to fund all of the trials Jennifer just discussed and provides us with good cash runway after the last readout. In 2024, we anticipate average cash burn of roughly $9 million to $12 million per quarter, and our fully diluted shares outstanding at December 1, 2023 is $114.5 million. That concludes our prepared remarks. I will now turn the call back to the operator for Q&A.
Leland Gershell
analystWe have a couple of questions. To start, regarding IPF and the CORAL trial design, I was hoping you could clarify the primary endpoints. Since you have 3 dose levels plus a placebo arm, will that primary endpoint — measured by 24-hour cough frequency — compare the pooled cough frequency for all 3 doses against placebo? Or instead, will it look at each dose level separately versus placebo?
Jennifer Good
executiveDavid, please go ahead.
David Clark
executiveLeland, thanks a lot for asking that; the way we'll look at it is dose by dose — high dose, mid dose, and low dose, each one measured on its own against placebo. Getting a solid read on dose response matters to us, and doing the analysis that way lets us achieve that.
Leland Gershell
analystAll right; that's quite useful. Then for my second question, I was just thinking, Jennifer, perhaps you might weigh in on the data that came out not long ago from a brief study involving low-dose controlled morphine for IPF offsetting, where a 40% decrease in cough was observed relative to placebo — though bearing in mind this was a trial lasting only 2 weeks, and naturally, morphine as opposed to nalbuphine?
Jennifer Good
executiveYeah. That's a fair question. Regarding the PACIFY trial, conducted in the U.K., I believe, Leland, what we took from it was that its success didn't come as a shock. The mechanism is something we have faith in. Our view is that the opioid pathway is effective. At the same time, we're convinced that having our drug act synergistically at both kappa and mu matters. That, I'd say, explains why morphine delivers a 40% reduction while nalbuphine shows 76% or 74% reduction. So our expectation was always that it would succeed, and we figured our drug would probably do even better. Another issue with morphine, I'd note, is essentially that respiratory depression means there's a ceiling on dosing. Those doses must be kept extremely low. Consequently, that will always somewhat restrict how far they're able to push it.
Nathanael Charoensook
analystNat Charoensook here, filling in for Tom Smith. Nice work on the strides taken during 2023. We've got a few things to ask; starting off, for the CORAL trial you're intending to run a sample silo estimation. Could you take us through why that's being done and how the sample silo estimation process works? Also, could you go over once more how many clinical sites you're targeting and how those break down between the U.S. and sites outside the U.S.?
Jennifer Good
executiveYes. David is going to handle this one.
David Clark
executiveAbsolutely, and thanks so much for asking that. The reason behind this really comes down to safeguarding the trial. In the Phase IIa study, we think we observed an effect that carries a lot of clinical significance, just as we laid out. As a result, we don't want to be exposed to a scenario where the numbers we're relying on for the effect size as we head into the CORAL study — where we've presumed 36% — turn out to be off. Compared with the placebo-corrected effect size of more than 50% that we observed in the Phase IIa study, we feel we've been suitably cautious. Even so, we wanted protection against a case where the effect size might remain clinically meaningful, since — as you're aware — specialists in this area consider an effect size of 20% to 30% on objective cough to be clinically relevant. So what we've accomplished through the powering and the SSRE, which backs this up, is that should our effect size be smaller than what appeared in the Phase IIa but still clinically relevant — say 25% — we're able to pick that up by using a larger sample size.
Jennifer Good
executiveYeah, and I'd also mention, David, that not much research has been carried out in this field, correct? Our small CANAL study was one additional fairly sizable trial. All the rest either didn't work or were too small. So you're calculating power without much data to go on. That's why it seemed logical, I think. Would you like to handle this one as well — the count of targeted sites and do <<inaudible>>?
David Clark
executiveRight, so for the CORAL study, our plan involves roughly 60 sites, give or take. At this point, most of those sites sit outside the U.S. — mainly across the EU and the U.K. Beyond that, we've got sites getting underway in Australia, plus other areas — Australia, Chile, and Canada. Those represent the key regions and nations where we're currently active and where we're making plans.
Nathanael Charoensook
analystUnderstood. That's quite useful. Just one more item, then. Regarding the Phase IIa gathering with the FDA concerning Haduvio in Prurigo Nodularis — is that something you've had? And what came out of that meeting, plus how are things going with partnership talks?
Jennifer Good
executiveWell, yes. It's a fair thing to ask. As should be clear given how late in the year it is, we haven't submitted a request yet for an end of Phase II meeting; David and his group were basically stretched to the limit getting those studies launched and operational. There's one additional one we're keen to get going. Beyond that, we're finalizing each of the reports and drafting whatever is required; at some point the share will submit a request for an end of Phase II meeting; it simply hasn't ranked as a priority. So in time, we'll reach that point. As of now, we haven't done it.
Serge Belanger
analystSo I suppose this one's for Jennifer and David. I'm just wondering what sort of lessons or KOL input you picked up after the FDA adcom concerning Merck's P2X3 candidate, plus that second CRL. I'm just wondering whether anything has shifted when it comes to the clinical development strategy, or in terms of how you see the market opportunity for refractory chronic cough?
Jennifer Good
executiveDavid and I are glancing at one another, since either of us could take this one. I'll offer a few remarks, and then I'll hand it to David. Basically, I believe in the end, beyond what everyone observed in the briefing book and heard while listening to the meeting, we additionally checked in with KOL at our own advisory Board to confirm we weren't overlooking anything. Essentially, the Merck drug simply lacked sufficient efficacy to get over the hurdles and got stuck, and the primary endpoint didn't correlate with the pros, and so on. So I think when all was said and done, that was the story, I'd say, and then I'll let David weigh in. The other lesson I definitely took away from listening to the Adcom was simply how powerful the patient stories were regarding how disruptive RCC is to their lives; that had an enormous impact on me. And I think you heard it from the panel, and you heard it from the FDA acknowledge that, that this is a — it's a serious disease. Having observed that journey across the last 5 years, when there was some debate over whether this was a real sort of condition. I think that ship has clearly sailed. I left that call feeling that the FDA has bought in and the patients did a really good job of making the case. So David, from as a drug developer, what do you hear?
David Clark
executiveThat matches my view. There are just 2 things I'd put on top of that. On the efficacy side — that's what we believe could set our program apart. Should we manage to translate the effect size observed in the IPF cough population into the RCC population, which we'll be looking at in Phase IIa and, we hope, in trials that follow, then that's a differentiator that genuinely shields us from what that Merck program ran into, as you put it, Jennifer. The second thing I'd mention: there are a great many lessons you already know of from the BELLUS program, which is now GSK's, that have been put in place, and I think the field as a whole — plenty of KOLs were telling us this — has absorbed a lot from all these programs that have been run, and we're able to make use of that. With luck, we do well in Phase IIa and RIVER and then move out into the bigger trials. There's a great deal of useful learning that works in our favor.
Jennifer Good
executiveSure. Being the pioneer who goes over the wall first in a fresh situation is never a simple thing. That said, it definitely lightens our load.
William Wood
analystIt's William here, filling in for Mayank. Nice work on that strong quarter to close the year. Regarding your Phase IIa RIVER and HAP trials, will you be telling us when you've got full enrollment or the last patient dosed, so we get a bit more clarity on when to expect those readouts? And since the HAP trial is already past 50% enrolled, should we figure it will report first? I've got a few more questions after this.
Jennifer Good
executiveYes. Thanks for asking, William. What you should anticipate from us is that we'll inform people once a study begins, and we'll provide direction on when we believe the top line data readout will come. We'll also, I think, tell people once we reach the 50% enrollment point, which lets investors and analysts understand if we're at the earlier part of enrollment or the later part; and we'd announce the last patient in. That's a fairly significant milestone; so what we want to steer clear of is giving an update each time on roughly where enrollment stands, because that just becomes painful for everyone involved. So that's how we're looking at it right now.
William Wood
analystThat's useful. And a fast follow-up about that. Since these readouts could land so near one another, both during the second half of '24, how do you intend to meet with the FDA to talk over next steps? And for the HAP trial in particular, do you, and maybe some conversation regarding REMS or a few of the regulatory things being put in place given the readout here, how should we view that? And would it be a single meeting? And then — and I'm leaving out those will be kind of folded into subsequent trials down the road?
David Clark
executiveRight. So the way we're thinking now is we're making preparations at this moment with experts in these viability field so that we're set once that data arrives to truly expect to question it alongside them and obtain their expert view. And after that, you're absolutely correct, then reach our decisions, all right, what do we believe is the sensible next steps for whatever further conversation with the regulators. So that's what we're planning as of now.
Jennifer Good
executiveAlso, David, that likely rolls into the end-of-Phase-II conversation regarding IPF at the earliest, correct? Since that's going to be a scheduled meeting. As for whether we decide to handle anything as a separate matter, that really only makes sense if there's a particular finding in the data we feel needs highlighting. So my expectation, William, is that when the end-of-Phase-II meeting for IPF happens, we'll gather everything together and likely talk it through at that point. I failed to address what you'd asked. Incidentally, I recall you'd wanted to know which one we believed would arrive first. And you're correct. Given that the HAP study requires just 56 subjects and we've got over 50% enrolled, my guess is that trial will read out before the other.
William Wood
analystAll right, that's helpful. Then perhaps for my final question, regarding the RIVER trial — it is stratified, clearly, as you mentioned, with the primary endpoint involving a cost reduction. At the point when top line results come out, ought we to look for that breakdown so we can gain a clearer picture of efficacy across those subpopulations? Or maybe simply some additional detail about what to anticipate from the top line readout when it happens?
David Clark
executiveYes. No, your assumption is right. Our plan — we are examining the overall population along with those 2 subpopulations, which is what we will be analyzing, and we intend to report those findings alongside the top line data readout.
Jennifer Good
executiveThanks. When it comes to clinical trial data for Haduvio, we anticipate a landmark year; an exciting path lies before Trevi, and we’re eager to concentrate on carrying out our clinical trials so we can reach data in these key indications starting in the latter half of this year. We’d like to express our gratitude to everyone for joining today’s call, and after it concludes we’ll be around to address any follow-up questions you might have. Thank you.
Operator
operatorThis call is now finished. We appreciate your participation in today's presentation. You are free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.